Related Experiment Video
Updated: Jun 19, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Use of botulinum toxin type A in poststroke spasticity
1Indiana University School of Medicine, 550 University Blvd, Rm. 6620, Indianapolis, IN 46202, USA. abrashea@iupui.edu
Expert Review of Neurotherapeutics
|October 9, 2009
Summary
Botulinum toxin type A injections effectively treat post-stroke upper extremity spasticity, improving patient function and quality of life. This safe and effective treatment demonstrated sustained benefits over 12 weeks with minimal side effects.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Pharmacology
Background:
- Post-stroke spasticity affects upper extremity function and quality of life.
- Overactive muscles following a stroke lead to significant disability.
- Current treatments aim to reduce muscle tone and improve functional outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of botulinum toxin type A for post-stroke upper extremity spasticity.
- To assess the impact of botulinum toxin type A on muscle tone and functional disability.
- To determine the duration of benefits and side effect profile of the treatment.
Main Methods:
- A large, multicenter, double-blind, placebo-controlled trial was conducted.
- Patients with post-stroke spasticity of the hand and wrist received botulinum toxin type A injections.
- Muscle tone, functional disability, and side effects were assessed over a 12-week study period.
Main Results:
- Botulinum toxin type A treatment significantly improved muscle tone.
- Patients experienced notable improvements in functional disability.
- Benefits were sustained throughout the 12-week study duration.
- Reported side effects were mild and self-limited.
Conclusions:
- Botulinum toxin type A injections are a safe and efficacious treatment for upper extremity spasticity after stroke.
- The treatment offers significant functional improvements and enhanced quality of life for patients.
- Botulinum toxin type A should be considered a first-line therapy for this condition.
Related Concept Videos
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:29Tetanus
Tetanus is a life-threatening neurological disorder characterized by persistent muscle contractions and spastic paralysis. It is caused by Clostridium tetani, a motile, Gram-positive, rod-shaped, obligate anaerobe. These bacteria produce terminal endospores, giving them a distinctive “lollipop” or “tennis-racket” appearance. They thrive in anaerobic environments, such as those found in deep puncture wounds.Once introduced into the body, the spores germinate into vegetative cells. These cells...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...